Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Equity Average (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Equity Average data on record, last reported at -$15.3 million in Q3 2025.

  • For Q3 2025, Equity Average fell 182.85% year-over-year to -$15.3 million; the TTM value through Sep 2025 reached -$15.3 million, down 182.85%, while the annual FY2024 figure was $21.1 million, 49.31% down from the prior year.
  • Equity Average reached -$15.3 million in Q3 2025 per MBRX's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $86.6 million in Q2 2021 and bottomed at -$15.3 million in Q3 2025.
  • Average Equity Average over 5 years is $42.8 million, with a median of $43.0 million recorded in 2023.
  • Peak YoY movement for Equity Average: skyrocketed 460.19% in 2021, then plummeted 182.85% in 2025.
  • A 5-year view of Equity Average shows it stood at $80.1 million in 2021, then crashed by 30.98% to $55.3 million in 2022, then plummeted by 40.27% to $33.0 million in 2023, then plummeted by 56.68% to $14.3 million in 2024, then plummeted by 206.59% to -$15.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$15.3 million in Q3 2025, $5.1 million in Q2 2025, and $12.5 million in Q1 2025.